SFTPD and idiopathic pulmonary fibrosis: Our data suggest that nintedanib may have effects on circulating levels of SP-D and CA-125, markers of epithelial dysfunction, a critical and early event in the pathogenesis of IPF [2], over as little as 4 weeks, although it cannot be determined from these data whether nintedanib has a direct effect on the epithelium.